InMed Pharmaceuticals' shareholders re-elected all board members and approved a share issuance plan on December 17, 2025.

InMed Pharmaceuticals held its 2025 annual meeting on December 17, with 35.43% of shares represented. Shareholders re-elected all six board members, each receiving over 81% support, approved auditors CBIZ CPAs P.C., and backed a plan to issue up to 20% of common shares under a Standby Equity Purchase Agreement, complying with Nasdaq rules. The company, developing drugs for Alzheimer’s, eye, and skin conditions targeting CB1/CB2 receptors, noted its statements include forward-looking risks. Results were filed with SEDAR+ on December 17.